| Autor: |
Thibaut Molinié, Giovanni Marsicano, Andreas Bikfalvi, Joris Guyon, Ignacio Fernández-Moncada, Irati Romero-Garmendia, Heidi Espedal, Gro V. Røsland, Rolf Bjerkvig, Hrvoje Miletic, Aurélien Barré, Marie-Alix Derieppe, Justine Rudewicz, Konrad Grützmann, Boutaina Daher, Thomas Daubon, Nina Obad, Macha Nikolski, Claire Larrieu, Barbara Klink, Céline Léon, Tiffanie Chouleur, Cyrielle Bouchez, Aurelien Coffe, Benjamin Dartigues |
| Přispěvatelé: |
Institut de biochimie et génétique cellulaires (IBGC), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS) |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
Lactate is a central metabolite in brain physiology, involved in the astrocyte-neuron lactate shuttle, but also contributes to tumor development. Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults, recognized by angiogenic and invasive growth, in addition to its altered metabolism. By adapting their glycolytic or oxidative metabolism, GBM stem-like cells are able to resist chemo- and radiotherapy. We show herein that lactate fuels GBM anaplerosis by replenishing the TCA cycle in absence of glucose. Lactate dehydrogenases (LDH) catalyze the interconversion of pyruvate and lactate. Deletion of either LDHA or LDHB did not alter significantly GBM growth and invasion. However, ablation of both LDH isoforms led to a reduction of tumor growth, and, consequently, to an increase in mouse survival. Comparative transcriptomics and metabolomics revealed metabolic rewiring involving high oxidative phosphorylation (OxPhos) in the double LDHA/B KO group which sensitized tumors to cranial irradiation, massively improving mouse survival. Survival was also increased when control mice were treated with the antiangiogenic treatment, bevacizumab, and the antiepileptic drug, stiripentol which targets LDH activity. Taken together, this highlights the complex metabolic network in which both LDH A and B are integrated and underscores that combined inhibition of LDHA and B is necessary to impact tumor development. Targeting of these enzymes in combination with anti-angiogenic and repurposed drugs may be of therapeutic benefit, especially when associated with radiotherapy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
